Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDH305 in IDH1 Mutated Low Grade Glioma
NCT02987010Phase 2Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- Jan 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of idh305 in low-grade glioma (LGG) (2 cohorts), sponsored by UT Southwestern Medical Center. Primary endpoints: IDH305 treatment of 2HG and 2HG response to IDH305 up to 365 days. Planned start Jan 2017; status: withdrawn.
02
Drugs
idh305
03
Conditions
low-grade glioma (LGG)
Beyond the preview
Go deeper on NCT02987010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02987010.